Silence Therapeutics (SLN) Assets (2019 - 2025)
Silence Therapeutics (SLN) has disclosed Assets for 7 consecutive years, with $131.4 million as the latest value for Q4 2025.
- Quarterly Assets fell 35.13% to $131.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $131.4 million through Dec 2025, down 35.13% year-over-year, with the annual reading at $131.4 million for FY2025, 35.13% down from the prior year.
- Assets hit $131.4 million in Q4 2025 for Silence Therapeutics, down from $146.8 million in the prior quarter.
- In the past five years, Assets ranged from a high of $202.6 million in Q4 2024 to a low of $116.4 million in Q4 2023.
- Historically, Assets has averaged $150.5 million across 5 years, with a median of $139.1 million in 2025.
- Biggest five-year swings in Assets: skyrocketed 74.01% in 2024 and later tumbled 35.13% in 2025.
- Year by year, Assets stood at $129.7 million in 2021, then fell by 2.76% to $126.1 million in 2022, then decreased by 7.65% to $116.4 million in 2023, then surged by 74.01% to $202.6 million in 2024, then crashed by 35.13% to $131.4 million in 2025.
- Business Quant data shows Assets for SLN at $131.4 million in Q4 2025, $146.8 million in Q3 2025, and $165.2 million in Q2 2025.